Emyria Ltd's (ASX:EMD) Michael Winlo tells Proactive that clinical data from one of its personalised care plans for opioid users has been validated in a world-first data linkage project. The company's been evaluating whether a treatment plan that involves care at its clinical services arm and a cannabinoid formulation can relieve a patient’s reliance on opioid medications to treat their chronic pain.
Emyria says its clinical data on opioid users has been validated in new world-first project
